Skip to main content

Idexx Laboratories Inc. Value Stock - Dividend - Research Selection

Idexx

ISIN: US45168D1046 , WKN: 888210

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

IDEXX Laboratories, Inc., together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. It operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. The company provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. It also offers diagnostic and health-monitoring products for livestock, poultry, and dairy markets; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers that are used in the human point-of-care medical diagnostics market. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was founded in 1983 and is headquartered in Westbrook, Maine.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Here's Why IDEXX Laboratories (NASDAQ:IDXX) Has Caught The Eye Of Investors

2026-02-15
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...

IDEXX Laboratories Inc. (IDXX) Shows Resilience as Analysts Reassess Targets

2026-02-15
IDEXX Laboratories Inc. (NASDAQ:IDXX) is one of the best medical technology stocks to invest in. On February 3, BTIG lowered its price target on IDEXX Laboratories Inc. (NASDAQ:IDXX) to $800 from $830 and maintained a Buy rating. The firm cited concerns about IDEXX’s 2026 guidance despite robust Q4 2025 earnings performance. IDEXX reported strong fourth-quarter […]

Welltower a fantastic stock to own amid AI disruption, says G Squared's Victoria Greene

2026-02-13
Victoria Greene, G Squared Private Wealth CIO, joins 'The Exchange' to discuss Greene's investing take on Welltower, TJX and IDEXX Labs.

IDEXX Laboratories to Present at Two Institutional Investor Conferences

2026-02-12
WESTBROOK, Maine, February 12, 2026--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, will participate in two upcoming conferences:

Insider Unloading: George Fennell Sells Options, Realizes $7.32M

2026-02-12

Baron Partners Fund is Leveraging IDEXX Laboratories’ (IDXX) Long-Term Growth Drivers

2026-02-11
Baron Fund, an investment management company, released its Q4 2025 letter for “Baron Partners Fund”. A copy of the letter can be downloaded here. The Fund increased considerably in the fourth quarter, returning 19.07% (Institutional Shares). It outperformed both the Russell Midcap Growth Index (the Benchmark), which returned -3.70%, and the broader Russell 3000 Index, […]

IDEXX Laboratories Inc. stock outperforms competitors on strong trading day

2026-02-10
IDEXX Laboratories Inc. stock outperforms competitors on strong trading day

Piper Sandler Maintains Neutral on IDEXX Laboratories, Lowers Price Target to $750

2026-02-09
Piper Sandler analyst David Westenberg maintains IDEXX Laboratories (NASDAQ:IDXX) with a Neutral and lowers the price target from $775 to $750.

IDEXX Laboratories, Inc. (IDXX): A Bull Case Theory

2026-02-07
We came across a bullish thesis on IDEXX Laboratories, Inc. on MTC’s Substack. In this article, we will summarize the bulls’ thesis on IDXX. IDEXX Laboratories, Inc.’s share was trading at $643.59 as of February 5th. IDXX’s trailing and forward P/E were 49.20 and 45.25 respectively according to Yahoo Finance. IDEXX Laboratories, Inc. develops, manufactures, and distributes products […]

How Investors May Respond To Piper Sandler Companies (PIPR) Adding Stuart Essig To Its Board

2026-02-06
Piper Sandler Companies recently elected Stuart M. Essig, Ph.D., to its board of directors, expanding the board from nine to ten members and appointing him to the Audit Committee for an initial term running through the 2026 annual shareholder meeting. Essig’s long career leading and advising healthcare and medical technology businesses, including his roles at Integra LifeSciences and IDEXX Laboratories, aligns closely with sectors that matter for Piper Sandler’s investment banking...